Correlation between Ploidy and Prognosis in Prostatic Carcinoma

Tavares, Amândio S.; Costa, João Pedro Leite Silva; Maia, J. Costa

doi:10.1016/s0022-5347(17)60513-5

Cited by 56 publications

(15 citation statements)

References 5 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…The survival data demonstrate a significant prognostic value of DNA measurement prior to treatment in prostatic cancer. This is in agreement with earlier published data (12,14 …”

Section: Discussionsupporting

confidence: 94%

Nuclear DNA cytophotometry in prostate carcinoma

Seppelt

Sprenger

1984

Cytometry

View full text Add to dashboard Cite

Cytologic evaluation of aspired samples of palpable nodules in the human prostate developed into a routine method, since Esposti (5) classified carcinoma with high (Gl), moderate (G2), and poor (G3) differentiation and evaluated the prognostic importance.The malignant cells frequently have a different DNA content than do normal cells (1,3,7,8,13). The purpose of this study was to determine the DNA content of prostate cancer cells before and during endocrine therapy, to compare it with the cytologic grading, the clinical state, and to evaluate possible prognostic factors. MATERIALS AND METHODSEighty patients with freshly diagnosed prostatic cancer underwent transrectal fine-needle aspiration biopsy prior to treatment (6). The biopsies were taken fanlike from the suspected area and neighboring unsuspected areas. Later repeat biopsies were taken from the same tumor region at 6-(n = 76) and 12-month intervals (n = 70) in surviving patients. The corresponding clinical state of complete or partial remission, stable disease, or progression was defined according to Schmidt et a1 (9).It was judged by digital rectal examination, percutaneous transvesical sonography, serum acid phosphatase activity, and radionuclide bone scan, followed by skeletal radiography in positive cases. Twenty patients with benign prostatic hypertrophy served as controls.The biopsied specimen was used for cytologic morphologic grading (5) and for single-cell fluorescence photometry (10-121, performed with the microscope photometer MPV 2 (Leitz, Wetzlar, West Germany).The samples were fixed with Merckofix spray and stored at +4-+8"C for the staining procedure. The samples were fixed again for 30 min in 96% ethyl alcohol and hydrolyzed in a thermostatic-controlled water bath at +28 f 0.2"C in 4N hydrochloric acid. Then 0.01% acriflavine-Schiff (Serva, Heidelberg, West Germany) was used for nuclear staining at room temperature for 1 hour. The samples were washed in SO2 solution, dehydrated in alcoholic solution, immersed in xylol for 5 min, and covered with nonfluorescent Cargille Oil (Cargille Laboratories, Cedar Grove, NY). This oil had a nucleuslike refractive index of nk0 = 1.54.About 100 cells were measured in every preparation. Normal prostate cells and leukocytes were used for evaluation of the normal diploid 2c DNA content. The values were displayed as histograms and analyzed statistically with the median-quartile test (2), because the DNA values differed in most cases from a normal distribution.Five parameters were extracted from the distribution of the DNA values and were used for the analysis. These parameters were the minimum, first quartile, median, third quartile, and maximum. A sixth parameter was Z, the 2c value, which was defined as the percentage of cells with a DNA content of 2c f 25% (12). RESULTSThe pretherapeutic DNA histograms had single peaks, were bimodal, or showed a broadly scattered DNA disAddress reprint requests to Dr.

show abstract

“…The survival data demonstrate a significant prognostic value of DNA measurement prior to treatment in prostatic cancer. This is in agreement with earlier published data (12,14 …”

Section: Discussionsupporting

confidence: 94%

Nuclear DNA cytophotometry in prostate carcinoma

Seppelt

Sprenger

1984

Cytometry

View full text Add to dashboard Cite

show abstract

“…These results confirm those of Tavares et al (1973) who yielded very good results with an estrogen therapy in welldifferentiated adenocarcinomas. Neither prostatec tomy, nor high X-ray radiation or heterosexual hormone therapy yielded acceptable results in grades 2 and 3.…”

Section: Results Regarding Staging and Gradingsupporting

confidence: 88%

Histological Grading of Prostatic Carcinoma and Its Clinical Evaluation

Bandhauer¹

1979

Eur Urol

View full text Add to dashboard Cite

“…While tumour staging and volume, serum prostate-specific antigen (PSA) measurements, histopathological grading and deoxyribonucleic acid (DNA) tumour ploidy status have all be shown to correlate with prognosis and survival (Tavares et al, 1973;de Vere White & Deitch, 1989;Gittes, 1991), no single method can reliably distinguish between potentially progressing tumours and those which will remain quiescent. New reliable criteria are thus needed to define the invasive and metastatic potential of individual prostate cancer cases.…”

mentioning

confidence: 99%

Matrix metalloproteinase 9 expression in primary human prostatic adenocarcinoma and benign prostatic hyperplasia

Hamdy

Fadlon²,

Cottam³

et al. 1994

Br J Cancer

116

View full text Add to dashboard Cite

Summary Matrix metalloproteinase (MMP) expression was investigated in patients with prostatic adenocarcinoma and benign prostatic hyperplasia (BPH). Forty-one men were studied: 26 had histologically proven prostate cancer, with 14 (54%) showing metastatic disease; 15 patients had BPH. Prostatic tissue was obtained from transurethral resection and needle core biopsies; gelatinolytic activity was determined by zymography. Seven gelatinolytic bands were detected, with molecular weights ranging from > 100 kilodalton (kDa) to 29 kDa. Nine of 14 patients (64%) with skeletal metastases had 92 kDa activity, present in only two of 12 patients (17%) with a negative bone scan, and absent in BPH. The 92 kDa gelatinolytic activity was expressed in 73% of aneuploid tumours compared with 20% of diploid tumours. A 97 kDa gelatinase was expressed in 80% of BPH samples and 23% of carcinoma patients. Enzyme bands of 72, 66 and 45 kDa were equally expressed in malignant tissue, irrespective of metastatic status, but were expressed in fewer BPH patients. The 97, 92, 66 and 45 kDa enzymes were identified as being pro-MMP-9 sequences by Western blotting, using a specific antibody directed against the pro sequence of the mature protein. MMP activity appeared to be increased in malignant prostatic tissue compared with BPH. Pro-MMP-9, in its 92 kDa form, was shown to be exclusively expressed by malignant prostatic tissue, and in particular by tumours that exhibited the aggressive and metastatic phenotype.Prostate cancer is the third most common malignancy in men in England and Wales, with over 9,000 new cases registered every year (Office of Population Censuses and Surveys, 1985).

show abstract

Correlation between Ploidy and Prognosis in Prostatic Carcinoma

Cited by 56 publications

References 5 publications

Nuclear DNA cytophotometry in prostate carcinoma

Nuclear DNA cytophotometry in prostate carcinoma

Histological Grading of Prostatic Carcinoma and Its Clinical Evaluation

Matrix metalloproteinase 9 expression in primary human prostatic adenocarcinoma and benign prostatic hyperplasia

Contact Info

Product

Resources

About